This review highlights that sepsis-induced cardiomyopathy is a reversible condition where routine use of dobutamine may be harmful, suggesting potential roles for levosimendan or mechanical support in severe cases.
Recognizes transient dysfunction to guide supportive care without premature interventions; leaves open targeted therapies amid mechanistic uncertainties.
Sepsis-induced cardiomyopathy is a reversible myocardial dysfunction that typically resolves in 7-10 days. It is characterized by left ventricular dilatation and depressed ejection fraction. However, many uncertainties exist regarding the mechanisms, characteristics, and treatments of this condition. Therefore, this review attempts to summarize our current knowledge of sepsis-induced cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Sato et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: